Changes in US stocks | Novavax Pharmaceuticals (NVAX.US) falls more than 19% FDA suspends clinical trials of its influenza vaccine

Zhitongcaijing · 10/16 15:57

The Zhitong Finance App learned that on Wednesday, Novavax Pharmaceuticals (NVAX.US) stock price fell sharply. As of press release, the stock had fallen more than 19% to $10.16. According to the news, the US Food and Drug Administration (FDA) suspended the company's planned clinical trial of the influenza vaccine. The clinical suspension was due to spontaneous reports of serious motor neuropathy events in a single CIC phase 2 trial participant.